Search Results

You searched for : LatestNewsonRedHill

	RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material ... Jan 02
	RedHill's phase 2/3 COVID-19 study of opaganib passes second DSMB with unanimous recommendation to continue Opaganib potentially minimizes likelihood of resistance due to viral mutations by targeting a human cell component involved in viral replication ... Dec 22
	The RedHill Phase II / III candidate opaganib reduces ARDS-related blood clotting in the preclinical model in COVID-19 patients The results also show that opaganib inhibits SARS-CoV-2 virus replication and proinflammatory markers in relevant preclinical models ... Dec 17
	RedHill announces DSMB unanimous recommendation to continue COVID-19 opaganib phase 2/3 study The independent, pre-programmed DSMB unanimously recommends the continuation of the global Phase 2/3 study of orally administered opaganib in severe COVID-19 pneumonia... Nov 23
	RedHill Biopharma initiates phase 3 study of RHB-204 for first-line treatment of NTM disease RHB-204 is being evaluated as a first-line, stand-alone, oral treatment for pulmonary nontuberculous mycobacteria (NTM) disease ... Nov 21
	RedHill Biopharma collaborates with 2 pharma companies for manufacturing of COVID-19 vaccine Opaganib demonstrated potent antiviral activity against SARS-CoV-2, completely inhibiting viral replication in an in vitro model of human lung bronchial tissue. ... Oct 22
6 Matching result(s) found!

-Advertisements-

Trending Now
	EV Conference 24---Charging Up for e-mobility Minister Ponnam Prabhakar and Jayesh Ranjan among others to graceJune 14, 2024
	Are we on track to end AIDS, end viral hepatitis and end STIs by 2030?June 14, 2024
	HR Conclave Focusing on Future-Forward Engineering where Engineering and Management students meet their future employees, thus exposing students to real-world HR challenges and innovative solutionsJune 14, 2024
	MAGGI Empowers 10 Women to Bring their Entrepreneurial dreams to lifeJune 13, 2024
	FTCCI announced its Annual Excellence Awards and invites entries, last date is 20th June 2024June 13, 2024
	Bird Flu Cases by Dr Praveen Gupta, Principle Director and Chief of Neurology, Fortis Hospital.June 13, 2024
	Sova Health's $1 Million Seed Funding to Drive Gut Health InnovationJune 13, 2024
	The Vital Role of Early Detection: Kevin Jonas on Battling Skin CancerJune 13, 2024
	Zumutor Biologics Advances Cancer Care with Novel Immunotherapy ZM008: A First-in-Class Anti LLT1 AntibodyJune 13, 2024
	HP Ghosh Hospital Unveils Innovative "Chest Tree" June 12, 2024
	Olympus Enhances Innovation Capabilities by Expanding R&D to Hyderabad, IndiaJune 12, 2024
	From the frontlines: Homeless person won over alcoholism, survived floods and defeated TBJune 12, 2024
	The Role of Hormones in Obesity: Why Men and Women Gain Weight DifferentlyJune 12, 2024
	Silent Killer: How a Young Mother’s Vision Loss Led to a Lung Cancer DiagnosisJune 12, 2024
	TruAlt Bioenergy’s subsidiary, Leafiniti Bioenergy supplies over 1000 tons of Compressed Biogas to AG&P Pratham in just 5 monthsJune 11, 2024
	Southeast Asia's Most Advanced Luxury Postpartum Centre Re'Joy Suites Opens in SingaporeJune 11, 2024
	Poor Muscle Health in Obesity Can be A Major Risk Factor for Early DeathJune 11, 2024
	Machine Learning Uncovers How Organ Ageing Impacts Health and LongevityJune 11, 2024
	Why Education is Essential for Health and LongevityJune 11, 2024
	New Study Reveals Antidepressant Withdrawal Symptoms Less Common but Still SignificantJune 10, 2024

Search Results

RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib

RedHill's phase 2/3 COVID-19 study of opaganib passes second DSMB with unanimous recommendation to continue

The RedHill Phase II / III candidate opaganib reduces ARDS-related blood clotting in the preclinical model in COVID-19 patients

RedHill announces DSMB unanimous recommendation to continue COVID-19 opaganib phase 2/3 study

RedHill Biopharma initiates phase 3 study of RHB-204 for first-line treatment of NTM disease

RedHill Biopharma collaborates with 2 pharma companies for manufacturing of COVID-19 vaccine

Trending Now